Conditions: Head and Neck Cancer Squamous Cell Carcinoma
Keywords: Head and Neck Cancer panitumumab
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 153
Healthy volunteers: no

Brief summary:
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed. The study is investigating if the addition of a targeted therapy (panitumumab) can improve the efficacy of chemoradiation without adding unmanageable toxicity.

Detailed description:

Arms:
arm 1: Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m\^2 and panitumumab 9 mg/kg on Days 1, 22 and 43. arm 2: Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m\^2 on Days 1, 22, and 43.

Interventions: intervention 1: Cisplatin intervention 2: Standard Fractionation Radiotherapy intervention 3: Panitumumab
Intervention descriptions: intervention 1: Administered intravenously (IV; in a vein) intervention 2: 70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions) intervention 3: Administered intravenously

Protocol document: